ALGS Stock Overview
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases.
Aligos Therapeutics, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$0.91|
|52 Week High||US$13.11|
|52 Week Low||US$0.86|
|1 Month Change||-3.12%|
|3 Month Change||-30.83%|
|1 Year Change||-92.12%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-93.85%|
Recent News & Updates
We're Keeping An Eye On Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn RateJul 11
We're Keeping An Eye On Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn RateFeb 02
Here's Why We're Not Too Worried About Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn SituationOct 19
We're Hopeful That Aligos Therapeutics (NASDAQ:ALGS) Will Use Its Cash WiselyMay 01
What Is The Ownership Structure Like For Aligos Therapeutics, Inc. (NASDAQ:ALGS)?Jan 16
|ALGS||US Biotechs||US Market|
Return vs Industry: ALGS underperformed the US Biotechs industry which returned -11.2% over the past year.
Return vs Market: ALGS underperformed the US Market which returned -21.2% over the past year.
|ALGS Average Weekly Movement||9.6%|
|Biotechs Industry Average Movement||11.1%|
|Market Average Movement||7.4%|
|10% most volatile stocks in US Market||15.5%|
|10% least volatile stocks in US Market||3.3%|
Stable Share Price: ALGS is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: ALGS's weekly volatility (10%) has been stable over the past year.
About the Company
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion; and ALG-055009, a small molecule THR-ß agonist that is in the Phase 1a/1b for the treatment of non-alcoholic steatohepatitis(NASH).
Aligos Therapeutics, Inc. Fundamentals Summary
|ALGS fundamental statistics|
Is ALGS overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ALGS income statement (TTM)|
|Cost of Revenue||US$94.58m|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-2.61|
|Net Profit Margin||-1,041.95%|
How did ALGS perform over the long term?See historical performance and comparison